CRISPR-based gene editing has emerged as a transformative tool in cancer therapy, offering precise and efficient manipulation of the genome to target genetic mutations driving tumor growth. This review discusses various CRISPR-based strategies for cancer therapy, including inactivating oncogenes, enhancing immune responses, repairing genetic mutations, and delivering cancer-killing molecules. Preclinical studies and clinical trials have demonstrated promising results, but challenges such as off-target effects, safety, and delivery to tumor sites remain. The review highlights the potential of CRISPR in developing personalized and effective cancer treatments, while emphasizing the need to address technical and ethical challenges. Key strategies include inactivating oncogenes like MYC, enhancing immune responses through PD-1 modification, repairing BRCA1/2 mutations, and engineering immune cells for targeted therapy. Challenges include ensuring specificity, minimizing unintended genetic changes, and improving delivery methods. Future research should focus on optimizing CRISPR-based therapies for clinical application, ensuring safety, and addressing ethical concerns. The review underscores the importance of continued research to harness CRISPR's potential in revolutionizing cancer treatment.CRISPR-based gene editing has emerged as a transformative tool in cancer therapy, offering precise and efficient manipulation of the genome to target genetic mutations driving tumor growth. This review discusses various CRISPR-based strategies for cancer therapy, including inactivating oncogenes, enhancing immune responses, repairing genetic mutations, and delivering cancer-killing molecules. Preclinical studies and clinical trials have demonstrated promising results, but challenges such as off-target effects, safety, and delivery to tumor sites remain. The review highlights the potential of CRISPR in developing personalized and effective cancer treatments, while emphasizing the need to address technical and ethical challenges. Key strategies include inactivating oncogenes like MYC, enhancing immune responses through PD-1 modification, repairing BRCA1/2 mutations, and engineering immune cells for targeted therapy. Challenges include ensuring specificity, minimizing unintended genetic changes, and improving delivery methods. Future research should focus on optimizing CRISPR-based therapies for clinical application, ensuring safety, and addressing ethical concerns. The review underscores the importance of continued research to harness CRISPR's potential in revolutionizing cancer treatment.